Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA).
Maxime DougadosJulien LucasEmilie DesfleursPascal ClaudepierrePhilippe GoupilleAdeline Ruyssen-WitrandAlain SarauxAnne TournadreDaniel WendlingCédric LukasPublished in: RMD open (2023)
Following its approval in France, ~59% of axSpA patients retained secukinumab in daily practice, at 1 year. Prior exposure to TNFi, OSI and IBD were identified as risk factors for secukinumab discontinuation.
Keyphrases
- ankylosing spondylitis
- end stage renal disease
- primary care
- healthcare
- ejection fraction
- newly diagnosed
- disease activity
- chronic kidney disease
- rheumatoid arthritis
- prognostic factors
- peritoneal dialysis
- quality improvement
- physical activity
- systemic lupus erythematosus
- patient reported outcomes
- ulcerative colitis
- drug administration